Culley Brian M 4

What Happened
Brian M. Culley, President, CEO and a director of Lineage Cell Therapeutics, purchased 15,000 shares in open-market transactions on March 12, 2026. The reported weighted-average price was $1.63 per share, for a total reported outlay of $24,375. This was a purchase (transaction code P), which is a direct acquisition of common stock.

Key Details

• Transaction date: 2026-03-12 (filed the same day) — appears timely.
• Shares purchased: 15,000 shares.
• Reported price: weighted average $1.63 per share; total reported value $24,375.
• Footnote: the $1.63 is a weighted average; individual trade prices ranged from $1.61 to $1.63. The filer offers to provide a breakdown of the number of shares at each price on request (SEC footnote).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Transaction code: P = Purchase (open-market).

Context
Insider purchases are often regarded by investors as a potentially bullish signal because executives are buying company stock with personal funds, but the filing does not state the insider's motivation. This was a straightforward open-market buy (not an option exercise, gift, or award).